Population Health
Neuro Suite
Standardize and automate neuroimaging analysis for WMH detection and brain volumetric quantification, leveraging quantitative measurements and normative data to deliver actionable insights for consistent, confident clinical decision-making at scale.
Discover key benefits
Standardized clinical excellence
Reduces interobserver variability with precise quantitative & objective measurements
Streamlined
workflows
Eliminates time-consuming work with automated measurement, segmentation and reporting
Diagnostic confidence
With automated WMH detection and atrophy quantification, providing longitudinal tracking to support early diagnosis
Optimized performance at scale
Smooth integration with existing systems, delivering standardization with a unified clinical and operational experience
With a modular design to meet your unique clinical needs
Cloud-native, accessible from anywhere
Automated & standardized reporting
Incorporates FreeSurfer
Brain Health
Provides automatic localization of WMH regions and segmentation of the boundaries for accurate measurements.
Provides automated segmentation and objective assessment of total WMH volume, lesion count, and anatomical distribution.
Distinct color-coding for periventricular, deep white matter, juxtacortical, and infratentorial regions overlays on FLAIR images, enabling immediate visual assessment of lesion distribution patterns critical for differential diagnosis support.
Tracks progression when prior exams are available, classifies lesions as new, enlarging, stable, or shrinking, and generates automatic graphs of WMH volume changes.
Provides automated segmentation of brain structure and accurate assessment of changes in volume.
Color-coded anatomical overlays on standard PACS viewers enable immediate visual assessment of brain structures.
Delivers quantitative measurements of region volume for comparison to prior exams and normative age- and sex-matched databases with percentile rankings that identify deviations from expectations.
Looking for the right solution? Schedule your demo.
Book a demo
"Using DeepHealth's Neuro Suite of products enables us to provide our clinicians with valuable objective information derived from our MRI scans.
Comparing the patient's results to a non-biased reference population makes it easier for clinicians to give patients insights into their atrophy development."
Dr. Mario Muto
Director Diagnostics and Interventional
Neuroradiology
Caradelli Hospital, Naples
"During our MDT meetings, we always pull up the report from DeepHealth's Neuro Suite of products and use it as extra information to come to a joint decision on the best diagnosis and clinical management of the patient."
Prof. Meike Vernooij
Population Imaging, Erasmus MC Rotterdam
Keeping the patient at the center is our primary goal
Professors Giovanni Capobianco and Marco Guazzaroni from ASL Roma 2, the Regional Health Authority of Rome worked with DeepHealth's AI-powered solution to segment the brain and prevent the progression and worsening of mild cognitive impairments through a collaborative multi-disciplinary approach.
Book a demo
Transforming population health with AI-powered diagnostic screening programs
Explore our visionCould healthcare begin before illness ever shows up? Rather than waiting for patients to experience symptoms, what if care started with prevention, early detection, and access to critical diagnostic tools?
Finding and treating diseases, like cancer, at earlier stages increases survival rates.1 Screening healthy people helps make early detection more possible. By expanding screening for a range of diseases, more people have the chance to stay healthy longer—and this shift has the potential to significantly transform population health.
Population Health Suite of Solutions
Orchestrate and scale high-volume cancer screening and disease assessment programs.
Find out moreLearn more
How AI is Transforming Neurodegenerative Disease Detection and Management
The human brain is one of medicine’s most complex and undiscovered frontiers. Find out how brain health, with the help of AI, could become as visible, measurable, and meaningful as other aspects of healthcare.
Reimagining population health: Fighting disease before it takes hold
References:
1) American Cancer Society. Breast Cancer Screening Guidelines, December 2023.
Available on the https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html.
(Accessed July 16, 2025)
Disclaimers: Neuro Suite is manufactured as Quantib ND by Quantib BV for DeepHealth Inc. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact us